Clinical Trials Browser

NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Phase 2 Completed

36 enrolled 19 charts

EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT04505553 2026-01-21

Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

Phase 2 Completed

78 enrolled 14 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Anus Neoplasms, Appendiceal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Clinical Trials

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

ArTisaN

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

TALENT

68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours

CABATEN

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors

Cabozantinib and Nivolumab for Carcinoid Tumors

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

DUNE

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver

NET-002

Phase 2 Study of ONC201 in Neuroendocrine Tumors

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

EVACEL

A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

HORMONET

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

NeoLuPaNET

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs

PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2

PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105

AveNEC

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

EPICentro

A Study of Pembrolizumab in Patients With Neuroendocrine Tumors

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

EVINEC

ATLANT

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

CSMS99

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

HEPAR_Plus

RADIONET

Lithium for Low-Grade Neuroendocrine Tumors

Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

ILUMINET

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Pazopanib as Single Agent in Advanced NETs

SONNET